Objective:
To evaluate the efficacy of a new stem cell treatment for patients with aniridia-related keratopathy (ARK).
Approach:
- Study Design: A first-in-human clinical trial involving nine patients with ARK, where one eye received the stem cell treatment and the other served as a control.
- Treatment Method: A collagen scaffold was engineered to deliver limbal epithelial stem cells and stromal stem cells to the damaged eye surface.
Key Findings:
- Treated eyes showed significant improvement in ocular surface scores, decreasing from 9.4 to 5.9 after three months and to 6.7 after twelve months.
- Untreated eyes showed minimal change, with scores starting at 8.4 and ending at 8.0 after one year.
- Vision improved by an average of 24 letters on the ETDRS eye test, equivalent to nearly five lines on a standard vision chart.
Limitations:
- The study involved a small sample size of only nine patients.
- Long-term effects and safety of the treatment remain to be fully evaluated.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
